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Background: Although the percentage of patients with renal cell carcinoma (RCC) extending into venous systems is
unexpectedly high, the prognostic impact and independency of venous tumor thrombus-related factors on overall
survival (OS) remain controversial. Furthermore, the prognostic impact of various clinicopathologic factors including tumor
thrombus-related factors on OS may change with elapsed years after the intervention and also with follow-up duration of
participants. The aim of the study is to explore independent and universal predictive preoperative and intraoperative
clinicopathologic factors on OS in patients with RCC extending into venous systems using subgroup analysis in terms of
restricted follow-up duration and yearly-based survivors.
Methods: Between 1980 and 2009, 292 patients diagnosed with RCC with venous tumor thrombus were retrospectively
registered for this study. The prognostic impacts of various clinicopathologic and surgical treatment factors including levels
of venous thrombus, venous wall invasion status and likelihood of aggressive cytoreductive operation, were investigated
using Kaplan-Meier method and following multivariate Cox proportional hazards model for all patients and those still alive
at 1, 2, and 3 years of follow-up. To investigate the impact of follow-up duration on the statistical analyses, multivariate
logistic regression analyses were used to explore prognostic factors using restricted data until 1, 2, and 3 years of follow-up.
Results: The median follow-up duration was 40.4 months. The 5-year OS was 47.6%. Several independent predictive
factors were identified in each subgroup analysis in terms of yearly-based survival and restricted follow-up duration. The
presence of tumor thrombus invading to venous wall was independently related to OS in the full-range follow-up data
and in survivors at 2 and 3 years of follow-up. Using restricted follow-up data until 1, 2, and 3 years of follow-up, many
independent predictive factors changed with follow-up duration, but surgical category could be universal and
independent predictive factors.
Conclusion: The most universal factors affecting improvement both in short-term and long-term survivals could be
cytoreductive surgery and absence of venous wall invasion. It may mean that feasible aggressive cytoreductive operation
following more reliable preoperative imaging for predicting venous wall invasion status would improve OS for patients
with RCC extending into venous systems.
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Although the incidence of small and incidentally detected
renal cell carcinoma (RCC) has increased, the percentage
of patients with tumor thrombus extending into the renal
vein (RV) or inferior vena cava (IVC) is unexpectedly high
at 4 to 10% of total patients diagnosed with RCC [1-4].
These patients usually need very careful management.
Therefore, a very experienced team including urologic
surgeons, general surgeons, and sometimes cardiologic
surgeons may be essential for perioperative management
because there may be a risk of operation-related death at
an unacceptable frequency.
Although many clinicians have investigated the impact
of tumor thrombus on survival of patients with RCC,
controversies surrounding this issue remain [5-9]. In
general, predicting prognosis of patients with very ad-
vanced stages of cancer is difficult because multifactorial
issues are often involved. In the view point of clinicians,
it is known that some clinicopathologic factors affect
short-term survival while others are related to long-term
survival. Controversy regarding the prognostic impact of
tumor thrombus in patients with RCC may be at least
partly due to the difference in the follow-up duration of
the recruited data in the previous studies.
To address the impact of classical clinicopathologic
factors, levels of tumor thrombus, venous wall invasion
and also likelihood of aggressive cytoreductive operation in
patients with RCC with venous thrombus on short-term
and long-term overall survival, the present comprehensive
univariate and following multivariate statistical analyses
were conducted using a multi-institutional data provided
by 17 hospitals in which all operations were performed by
experienced urologists who are members of the Japanese
Society of Renal Cancer.
Methods
Between October 1980 and March 2009, consecutive 292
patients diagnosed with RCC that extends into the RV,
IVC, or right atrium at 17 hospitals belonging to the
Japanese Society of Renal Cancer were retrospectively
registered in the present study. The year of registration
was 1980s, 1990s and 2000s in 8 (2.7%), 136 (46.6%)
and 148 (50.7%) patients, respectively. All participants had
pathologically confirmed RCC from surgical specimens in
patients who underwent operations or from transluminal
core-biopsy of the renal tumor, biopsy of metastatic lesions,
or aspiration cytology in those who did not undergo radical
nephrectomy. All patients underwent a bone scan and
chest, abdominal, and pelvic computed tomography
(CT) for clinical staging. Ninety one patients with distant
metastases were also enrolled in the present study in order
to investigate whether cytoreductive surgery was feasible
in such patients. The date of last follow-up was August 6,
2009. No patients were treated with molecular-targetedtherapy. All pretreatment clinicopathologic data were
collected from medical records by urologists in each
institution according to the checking sheet for the present
research. There was no restricted treatment strategy for
the use of interferon or interleukin in adjuvant or salvage
settings. There were no restricted follow-up criteria, but
blood examinations were done at least once in every
6 months until 5 years of follow-up and in every 6 month
thereafter. CT was conducted at least once in every
6 months until 5 years of follow-up and at least annually
thereafter, regardless of clinical symptoms. Individual
causes of death were judged and recorded by experienced
clinical urologists in each institution working in inpatient
clinics, most of whom were not associated with the
present study.
The levels of tumor thrombus extension were stratified
into five categories: (1)intrarenal vein, (2)infrahepatic IVC,
(3)suprahepatic IVC, (4)intrapericardial IVC, and (5)intra-
cardiac extension (right atrium) according to the classifi-
cation proposed by Cummings. Pretreatment prognostic
factors included age, clinical symptoms at diagnosis, opera-
tive experience in each hospital, performance status (PS)
as defined by the Eastern Cooperative Oncology Group,
hemoglobin (Hb) level, erythrocyte sedimentation rate
(ESR), serum lactate dehydrogenase (LDH) level, calcium
(Ca) concentration, C-reactive protein (CRP), immuno-
suppressive acidic protein (IAP), α2 globulin, and clinical
tumor features including lymph node metastasis, distant
metastasis and level of tumor thrombus. Pathological
prognostic factors included tumor nuclear grade, histo-
pathological subtypes, tumor diameter at origin, perinephric
fat invasion, invasion of RV/IVC walls. Invasive status of
RV/IVC walls was also judged clinically during operation
in some patients undergoing radical nephrectomy, but
having been unable to resect thrombus completely. Tumor
status and operative management at the tumor origin,
tumor thrombus, and metastatic sites were classified
into five surgical categories: 1) radical nephrectomy and
complete resection of thrombus without metastasis, 2)
radical nephrectomy and complete resection of thrombus
with metastases that has undergone a cytoreductive
surgery, 3) radical nephrectomy and complete resection of
thrombus with unresected metastases, 4) radical nephrec-
tomy and incomplete resection of thrombus regardless of
metastatic status, and 5) no operation.
Multivariate Cox proportional hazards model was
used to explore predictors on overall survival in all 292
participants. To clarify whether prognostic factors change
with elapsed postoperative follow-up years, impacts of
the above-indicated clinicopathologic factors were in-
vestigated for patients who were alive at 1, 2, and 3 years
of follow-up.
Furthermore, the prognostic impact of the above general
and tumor-related factors were also assessed using restricted
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vestigate the impact of follow-up duration on statistical
analyses of prognostic factors. This unique analysis using
restricted follow-up data may clarify prognostic factors
that affect short-term and/or long-term survival.
All statistical analyses were performed using Dr. SPSS II
(SPSS, Inc., Chicago, IL, USA) or Stat Flex (Ver.5.0; Artech
Co., Ltd., Osaka, Japan). Cause-specific survival (CSS) and
overall survival (OS) were estimated by Kaplan–Meier
analysis, and the significance of differences was evaluated
by the log-rank test. The above-mentioned candidate
prognostic factors were investigated in terms of their rela-
tionships with cause-specific death and all-cause death.
The cut-offs of continuous clinicopathological factors
for Kaplan–Meier analyses were explored by separating
patients into binary, tertiary, or quartiles to establish
more significant and meticulous separation. If two adjacent
subgroups were considered to have an equal predictive
value, they were combined. Categorized clinicopathologic
factors were also explored in terms of their best cut-lines
to establish more significant and meticulous separation.
Significant cut-lines for those factors were then explored,
and candidates for multivariate analyses were selected and
eliminated after considering Spearman’s rank correlation
coefficient. The Cox proportional hazard model or mul-
tiple logistic regression analysis was used to determine
independent and significant predictive factors. To determine
independent surrogate factors predictive of OS, a stepwise
multiple regression analysis was performed using forward
selection. In this analysis, all clinicopathological factors
were handled as categorical variables. Differences were
considered statistically significant at a p value of <0.05.
The ethics review committee of the institution of the
chief investigator (Isesaki Municipal Hospital) and the
individual institutional review boards of all participating
facilities approved this study.
Results
Of 292 patients with a tumor thrombus that extended
into the RV or IVC, 152 (52.1%) had a tumor thrombus
within the RV, 101 (34.6%) had a thrombus that extended
to the IVC below the hepatic vein (infrahepatic IVC), 20
(6.8%) had a thrombus that extended to the suprahepatic
IVC, and 11 (3.8%) had a thrombus that extended to
the intracardial IVC or right atrium. Table 1 shows the
clinicopathologic features of RCC extending into the
venous system as stratified by the level of tumor thrombus.
The gender, age, PS, CRP, tumor location, presence or ab-
sence of perinephric fat invasion/lymph node metastases/
distant metastases, nuclear grade, and pathological tumor
subtype were not significantly different among the levels
of tumor thrombus. Alternatively, patients with a tumor
thrombus within the RV had a lower ESR compared with
those with a tumor thrombus extending to the suprahepaticIVC. Patients with a tumor thrombus within the RV or
infrahepatic IVC had a lower IAP compared with those
that extended to the suprahepatic IVC.
A total of 196 (67.1%) patients underwent radical
nephrectomy and complete resection of thrombus without
apparent metastasis, 11 (3.8%) underwent radical nephrec-
tomy, complete resection of thrombus and cytoreductive
surgery at metastatic sites, 66 (22.6%) underwent radical
nephrectomy and complete resection of thrombus oper-
ation and with unresected metastasis, 8 (2.7%) underwent
radical nephrectomy and incomplete resection of thrombus,
and remaining 11 (3.8%) were unable to undergo oper-
ation. Table 2 shows correlations of operative status and
metastatic management with clinicopathologic features of
participants. Age , tumor size and tumor nuclear grade
did not affect operative and metastatic status/management
of patients, except for patients classified into surgical
category 4 who were younger than those classified into
surgical category 1, 3 or 5. Patients who were unable to
undergo operation (surgical category 5) had lower PS than
those underwent radical nephrectomy and complete
resection of thrombus (surgical category 1, 2 or 3). The
presence of perinephric fat invasion was significantly
lower in patients without metastasis undergoing radical
nephrectomy and complete resection of thrombus (surgical
category 1) than those undergoing radical nephrectomy
and complete resection of thrombus with resected or
unresected metastases (surgical category 2 or 3). Patients
with non-clear cell subtypes tended to unable to undergo
operation than those with clear cell subtype.
Table 3 shows the relationship between levels of tumor
thrombus and operative status in 284 patients who were
confirmed the level of tumor thrombus in the pretreatment
medical records. There were no significant trends between
extension of tumor thrombus and operative status, regard-
less of the metastatic status.
The median follow-up was 40.4 months (range; 0 to
278 months). A total of 133 patients died due to RCC
and 14 cases due to other causes. Death within one
month after operation or diagnosis was seen in 2 (18.2%)
of 11 patients who did not undergo operation and in 8
(2.8%) of 281 patients who underwent any operations.
Figure 1 shows OS in all participants and the 1-, 3-, 5-year
OS and CSS, respectively, were 77.4% and 79.0%, 55.2%
and 58.4%, 47.6% and 50.9%. Details of the impacts of
pretreatment, treatment, and pathological factors on OS
by Kaplan–Meier analyses are shown in Table 4. The op-
eration volume in each hospital, treatment era, and serum
calcium concentration were not predictive of OS, but all
other pretreatments, treatments, and pathological factors,
with the exception of tumor thrombus extension, were
significantly associated with OS in univariate analyses. OS
and CSS were not significantly different between patients
who were treated with and without immune therapies.
Table 1 Clinicopathologic features of renal cell carcinoma extending into the venous system stratified by level of
tumor thrombus













n 148 101 20 11 8 292
Gender (n)
Male 108 80 15 7 7 217 n.s.
Female 44 21 5 4 1 75
Age (years)
Mean ± S.D. 63.7 ± 10.8 60.8 ± 10.4 62.3 ± 11.8 60.6 ± 12.5 61.8 ± 11.4 62.4 ± 10.8 n.s.
Performance status (n)
0 105 73 11 5 3 197 n.s.
1 18 11 6 2 2 39
2 10 2 1 1 0 14
3 2 4 0 1 0 7
Unknown 17 11 2 2 3 35
ESR (mm)
Mean ± S.D. 56.5 ± 44.1 65.4 ± 43.7 81.7 ± 38.6 43.8 ± 57.2 93.3 ± 70.6 62.0 ± 44.6 p < 0.05; intra-renal vein
vs. suprahepatic IVC
CRP (ng/ml)
Mean ± S.D. 3.7 ± 4.9 4.0 ± 5.7 5.3 ± 5.6 1.7 ± 1.4 7.2 ± 10.0 3.9 ± 5.4 n.s.
IAP (ug/ml)
Mean ± S.D. 796.9 ± 420.5 794.4 ± 328.2 1020.4 ± 438.7 828.2 ± 372.9 789 ± 475 813.2 ± 391.4 p < 0.05; intra-renal vein,
infrahepatic IVC vs.
suprahepatic IVC
Tumor size classification (n)
<4 cm 17 5 1 2 0 25 n.s.
4-7 cm 40 22 5 4 2 73
>7 cm 90 70 11 4 4 179
Unknown 5 4 3 1 2 15
Tumor location (n)
Right 72 67 12 9 5 165 n.s.
Left 76 33 8 2 1 120
Bilateral 2 1 0 0 0 3
Missing data 2 0 0 0 2 4
Perinephric fat invasion (n)
No 56 38 12 5 3 114 n.s.
Yes 21 17 3 1 1 43
Unknown 75 46 5 5 4 135
Regional lymph node involvement (n)
No 74 29 10 4 1 118 n.s.
Yes 27 23 3 2 6 61
Unknown 51 49 7 5 1 113
Distant metastases (n)
No 100 60 12 8 3 183 n.s.
Yes 47 32 4 3 5 91
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Table 1 Clinicopathologic features of renal cell carcinoma extending into the venous system stratified by level of
tumor thrombus (Continued)
Unknown 5 9 4 0 0 18
Tumor nuclear grade (n)
G1 15 9 2 1 0 27 n.s.
G2 103 52 14 6 4 179
G3 29 38 4 3 1 75
Unknown 5 2 0 1 3 11
Histopathologic category (n)
Clear cell 112 67 17 7 3 206 n.s.
Papillary, chromophobe, others 28 29 3 4 3 67
Spindle, sarcomatoid 12 5 0 0 2 19
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extension, a nearly significant and a significant cut-line for
predicting OS was between patients with RV or infrahepatic
IVC extension and patients with suprahepatic IVC to
intracardiac extension (p = 0.0589) and between patients
with RV extension and patients with infrahepatic IVC to
intracardiac extension (p = 0.0288). There was no signifi-
cant difference in OS between patients with RV extension
and those with infrahepatic IVC extension.
Using selected factors that significantly predicted OS in
Kaplan–Meier analyses, multivariate analyses of independ-
ent and significant predictive factors for OS for all patients
and for those alive at 1, 2, and 3 years of follow-up were
performed using a multivariate Cox proportional hazards
model (Table 5). According to multivariate analyses using
full-range follow-up data, RV/IVC wall invasion and surgi-
cal category were significantly related to OS. According to
the partial investigation of survivors at 1 year of follow-up,
pathological subtypes and IAP were significantly related to
OS. RV/IVC wall invasion was strongly related to OS in
restricted survivors at 2 and 3 years of follow-up. The PS
was related to OS in restricted survivors at 2 and 3 years
of follow-up. Overall, RV/IVC wall invasion was a very
significant predictive factor for OS in the full range
follow-up and in survivors at 2 and 3 years of follow-up.
To investigate the impact of follow-up duration on OS,
multivariate logistic regression analyses were performed
using the restricted data until 1, 2, and 3 years of follow-up
(Table 6). Clinicopathologic factors taken into multivariate
analyses were selected according to the significance of
univariate analyses by Kaplan–Meier methods. Tumor size
was a significant predictive factor for OS for a short-term
follow-up of within 1 year. RV/IVC wall invasion was
significantly correlated with OS if the follow-up duration
was restricted to within 1 or 2 years. The surgical category
was very strongly correlated with OS in any datasets in
which the follow-up duration was restricted to within
1, 2, or 3 years. LDH and α2 globulin were significantlycorrelated with OS in a restricted follow-up duration
of within 2 or 3 years, but were not significant only using
restricted datasets within 1 year after interventions.
The operative and metastatic status/management (i.e.;
surgical category) and status of RV/IVC wall invasion were
the most universal predictive factors of OS in the
present series. Figure 2A shows OS stratified by
subdivided surgical categories into complete resection
at the origin and thrombus without metastasis (surgical
category 1), complete resection at the origin and thrombus
with metastases regardless of cytoreductive surgery (surgi-
cal category 2 + 3), and incomplete resection at the origin
and thrombus or no operation (surgical category 4 + 5).
Figure 2B shows OS stratified by presence or absence of
RV/IVC wall invasion. Those all subdivided categories
shown in Figure 2A and 2B could clearly predict OS.
Discussion
The prognosis of RCC that has extended into the RV or
IVC is comparable to that of RCC without tumor
thrombus [10-14]. Skinner et al. demonstrated that the
5- and 10-year OS were 55% and 43%, respectively, in
11 patients with non-metastatic RCC with a tumor
thrombus that extended into the IVC [12]. Furthermore,
Ficarra et al. demonstrated that the prognosis of patients
with a venous thrombus limited to the subdiaphragmatic
IVC was almost identical to that of patients with clinical
T2N0M0 disease if there was no perirenal fat invasion, or
lymph node or distant metastases [14]. In the present
study, 153 patients without apparent or pathological lymph
node or distant metastases including tumor thrombi that
extended to not only the infrahepatic IVC, but also the
suprahepatic IVC, achieved a relatively high 5-year OS of
67.0%. The risk of operation-related death was relatively
low at 2.8% in 281 patients who underwent operations.
The relationship between prognosis and the level of
tumor thrombus is controversial [1,3,5,9,15-23]. Some re-
ports have demonstrated that there was no relationship
Table 2 Correlations of operative and metastatic status/management with clinicopathologic features of renal cell carcinoma extending into venous system
Variables Operative status of RCC extending to the venous system and metastatic status/management Statistical significance (chi-square
test or Mann–Whitney U test)Radical nephrectomy and
complete resection of thrombus
Radical nephrectomy and
incomplete resection of thrombus











Surgical category 2 Surgical category
3
Surgical category 4 Surgical category
5
n 196 11 66 8 11
Age (years)
Mean ± SD 63.0 ± 11.0 57.5 ± 9.1 61.7 ± 9.8 54.3 ± 5.8 66.8 ± 13.8 p < 0.05; surgical category 4 vs.
surgical category 1, 3, 5
Performance status (n)
0 143 7 43 4 0 p < 0.05: surgical category 1, 2, 3 vs.
surgical category 5 surgical category
1 vs. surgical category 41 22 2 10 1 4
2 6 1 5 0 2
3 2 0 3 1 1
Unknown 23 1 5 2 4
Tumor size classification (n)
<4 cm 20 0 5 0 0 n.s.
4-7 cm 48 1 19 3 2
>7 cm 119 10 40 5 5
Unknown 9 0 2 0 4
Perinephric fat invasion (n)
No 86 3 20 5 0 p < 0.05: surgical category 1 vs.
surgical category 2, 3
Yes 22 4 16 1 0
Unknown 88 4 30 2 11
Tumor nuclear grade (n)
G1 18 1 5 3 0 n.s.
G2 129 7 42 1 0
G3 48 3 19 4 0
Unknown 1 0 0 0 11
Histopathologic category (n)
Clear cell 144 10 48 4 0 p < 0.05; : surgical category 1, 2, 3,
4 vs. surgical category 5 surgical
category 3 vs. surgical category 4Papillary, chromophobe, others 42 1 14 1 9


















Table 3 Correlation between levels of tumor thrombus extension and managed operation
Operative status Statistical significance
(chi-square test)Level of tumor thrombus Radical nephrectomy and
complete resection of thrombus
regardless of metastatic status
Radical nephrectomy and
incomplete resection of thrombus
regardless of metastatic status
Abandoned
operation
Surgical category 1, 2, 3 Surgical category 4 Surgical category 5
All patients (n = 284)
Intrarenal vein 146 2 4 n.s.
Infrahepatic IVC 95 4 2




Patients without apparent distant metastasis (n = 180)
Intrarenal vein 99 0 1 n.s.
Infrahepatic IVC 58 2 0




Patients without distant metastasis and lymphnode involvement (n = 82)
Intrarenal vein 54 0 0 n.s.
Infrahepatic IVC 19 0 1
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[1,3,5,15,17,18,20,21]. In contrast, others indicated differ-
ences in prognosis between patients with a tumor
thrombus that extended below the diaphragm (or hepatic
vein) and those that extended above the diaphragm
(hepatic vein) [6,16,22,23], and some investigators have





















Figure 1 Overall survivals after operation or any interventions in all pbetween patients with a tumor thrombus within the
RV and those with a thrombus that extended into the
IVC [8,9,19]. The controversy regarding the prognostic
significance of the level of tumor thrombus may have
resulted from differences in the backgrounds of the investi-
gated patients among institutions, progress in the operative
technique, mean follow-up duration, and the particulararticipants.
Table 4 Impacts of various pretreatment, treatment, and pathological factors on overall survival










All cases 292 147 68 14 47.6% 3.3%
Operation volume in each hospital (n)
1-9 29 13 3 1 40.9% 14.1% ns; any comparison
10-19 75 35 21 4 50.4% 6.5%
20-35 188 99 44 9 46.9% 4.1%
Treatment era
Before 1999 144 86 56 8 49.2% 4.4% ns
After 2000 148 61 12 6 43.4% 5.7%
Age (years old)
30-57 100 49 26 5 48.2% 5.6% p = 0.00561; Age 58–67
vs. Age 68-87
58-67 96 45 33 5 58.6% 5.5%
68-87 96 53 9 4 34.2% 6.1%
Performance status
0 197 82 47 8 55.8% 4.1% p = 0.00002
1-4 60 41 10 4 25.7% 6.4%
Operation
Yes 281 136 68 14 49.7% 3.4% p = 0.00000
No 11 11 0 0
ESR (mm/h)
Male: 0–49, female: 0-52 91 38 25 5 55.4% 6.0% p = 0.00024
Male:> = 50, female:> = 56 92 60 12 4 29.4% 5.7%
CRP (mg/l)
<1.3 129 47 33 5 61.0% 5.0% p = 0.00003
> = 1.3 126 78 21 7 32.9% 4.9%
α2 globulin (%)
3.2-10.5 76 27 20 5 60.9% 6.5% p = 0.00212
10.6-22.3 76 44 15 3 38.4% 6.6%
Ca (mg/dl)
3.8-9.1 99 49 24 4 49.1% 5.7% ns
9.2-14.1 100 45 20 4 49.7% 5.9%
LDH (U/l)
66-288 126 46 21 7 51.1% 6.0% p = 0.02171
289-1740 125 78 34 6 42.2% 4.7%
Hb (g/dl)
6.5-11.3 107 64 19 7 32.5% 5.5% p = 0.00250
11.4-18.5 103 45 27 2 57.7% 5.5%
IAP (μg/ml)
232-712 102 36 32 5 64.5% 5.3% p = 0.00000
713-2048 101 65 13 5 29.8% 5.5%
T_category
= < T3 275 134 68 13 49.8% 3.4% p = 0.00000
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Table 4 Impacts of various pretreatment, treatment, and pathological factors on overall survival (Continued)
T4 14 12 0 1 9.5% 8.8%
N_category
N0 118 55 32 6 55.8% 5.0% p = 0.00000
N1 + N2 61 41 3 4 13.0% 5.9%
M_category
M0 183 83 44 11 51.3% 4.3% p = 0.00002
M1 91 61 14 3 31.4% 5.3%
Surgical category
1 196 82 52 11 55.5% 4.1% p = 0.00007; surgical
category 1 vs. surgical
category 3
2 11 6 4 2 52.0% 15.7% p = 0.00022; surgical
category 1 vs. surgical
category 4
3 66 41 10 1 34.7% 6.6% p = 0.00000; surgical
category 1 vs. surgical
category 5
4 8 7 2 0 25.0% 15.3% p = 0.00342; surgical
category 2 vs. surgical
category 5
5 11 11 0 0 p = 0.00112; surgical
category 3 vs. surgical
category 5
Tumor size (cm)
0-8.3 141 60 41 7 59.6% 4.8% p = 0.0020
2:8.5-27 139 78 24 7 36.6% 4.7%
Pathological subtype





56 31 11 2 41.9% 7.6% p = 0.00000; clear cell vs.
spindle, sarcomatoid




G1 + G2 206 94 56 12 53.9% 3.9% p = 0.00215
G3 75 42 12 2 37.1% 6.7%
Capsular status
Non-invasive 114 55 34 5 52.5% 5.2% p = 0.00207; non-invasive
vs. invasive
Invasive 43 30 6 2 28.4% 7.6% p = 0.02827; incvasive
vs. unknown
Unknown 135 62 28 7 50.2% 5.1%
RV/IVC wall invasion
Non-invasive 133 52 39 6 59.5% 4.8% p = 0.00000; non-invasive
vs. invasive
Invasive 78 51 15 6 33.5% 6.2% p = 0.00107; non-invasive
vs. unknown
Unknown 81 44 14 2 41.3% 6.4%
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Table 4 Impacts of various pretreatment, treatment, and pathological factors on overall survival (Continued)
Tumor thrombus classification 1
Renal vein, infrahepatic
IVC extension
253 119 63 12 50.9% 3.6% p = 0.05890
Suprahepatic, intracardial
IVC, intracardiac extension
31 22 4 2 28.7% 9.4%
Tumor thrombus classification 2
Renal vein extension 152 66 41 5 55.1% 4.5% p = 0.02410; renal vein
vs. suprahepatic
IVC-intracardiac
Infrahepatic IVC extension 101 53 22 7 44.3% 5.9% ns; any other comparison
Suprahepatic, intracardial
IVC, intracardiac extension
31 22 4 2 28.7% 9.4%
Tumor thrombus classification 3




132 75 26 9 40.6% 5.0%
surgical category 1; radical nephrectomy and complete resection of thrombus without metastasis, surgical category 2; radical nephrectomy and complete resection of
thrombus with metastases that has undergone a cytoreductive surgery, surgical category 3; radical nephrectomy and complete resection of thrombus with unresected
metastases, surgical category 4; radical nephrectomy and incomplete resection of thrombus regardless of metastatic status, surgical category 5; abandoned operation.
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the levels of tumor thrombus. In the present study,
many available preoperative clinical and pathologic
factors were investigated by univariate analyses using
the Kaplan–Meier method.Table 5 Multivariate Cox proportional hazards model on pred
based survivors diagnosed with renal cell carcinoma extendin
Variables Estimate ±
All cases
Renal vein/ inferior vena cava wall invasion status 0.80 ±
Pathological subtype 0.45 ±
Surgical category 0.55 ±
Survivors at 1 year of follow-up
IAP 2.62 ±
Pathological subtype 0.53 ±
Survivors at 2 years of follow-up
Renal vein/ inferior vena cava wall invasion status 1.15 ±
PS 0.91 ±
Survivors at 3 years of follow-up
Renal vein/ inferior vena cava wall invasion status 1.60 ±
PS 0.89 ±
In the stepwise multiple regression analysis, 232-712 μg/ml IAP, 0 PS, radical nephre
category, non-venous wall-invasive thrombus in renal vein/ inferior vena cava wall
Similarly, 713–2048 μg/ml IAP, 1–4 PS, radical nephrectomy and complete resection
surgical category, venous wall-invasive thrombus in renal vein/ inferior vena cava w
subtype in pathological subtype are coded as 2.
Spindle or sarcomatoid pathological subtype, radical nephrectomy and complete resec
Radical nephrectomy and incomplete resection of thrombus regardless of metastat
Abandoned operation in surgical category is coded as 5.Furthermore, significant factors predicting OS may
change according to the follow-up duration, and these
differences may result in controversy in terms of the impact
of tumor thrombus extension on survival. Therefore, in
the present study, multivariate logistic regression analysesictors of overall survival in all participants and yearly-
g into renal vein or inferior vena cava
Standard error Hazard ratio p value
(95% Confident interval)
0.30 2.22 (1.22-4.02) 0.00876
0.24 1.57 (0.97-2.53) 0.06486
0.16 1.73 (1.25-2.39) 0.00088
0.50 13.68 (5.16-36.3) 0.00000
0.21 1.70 (1.11-2.59) 0.01371
0.44 3.16 (1.35-7.44) 0.00825
0.47 2.49 (1.00-6.25) 0.05122
0.48 4.96 (1.93-12.8) 0.00090
0.50 2.43 (0.91-6.44) 0.07531
ctomy and complete resection of thrombus without metastasis in surgical
invasion, and clear cell subtype on pathological subtype are coded as 1.
of thrombus with metastases that has undergone a cytoreductive surgery in
all invasion, and papillary/chromophobe//others excluding spindle or sarcoma
tion of thrombus with unresected metastases in surgical category are coded as 3.
ic status in surgical category is coded as 4.
Table 6 Impact of follow-up duration on overall survival in patients with renal cell carcinoma extending into venous
system: Multivariate logistic regression analyses using restricted follow-up data until 1, 2, and 3 years after
intervention
Variables Estimate ± Standard error Odds ratio p value
(95% Confident interval)
Restricted follow-up until 1 year
Surgical category 0.71 ± 0.19 2.03 (1.40-2.92) 0.00016
RV/IVC wall invasion status 1.06 ± 0.39 2.87 (1.33-6.20) 0.00721
Tumor size 0.69 ± 0.40 1.98 (0.91-4.34) 0.08591
Constant −4.15 ± 0.78
Restricted follow-up until 2 years
LDH 2.48 ± 0.94 11.96 (1.91-75.0) 0.00804
Surgical category 1.95 ± 0.52 7.04 (2.56-19.4) 0.00016
RV/IVC wall invasion status 1.99 ± 0.79 7.28 (1.56-34.0) 0.01152
α2 globulin 1.69 ± 0.80 5.44 (1.14-25.9) 0.03351
Constant −12.10 ± 2.86
Restricted follow-up until 3 years
LDH 1.02 ± 0.49 2.78 (1.07-7.25) 0.03621
Surgical category 0.86 ± 0.26 2.36 (1.42-3.92) 0.00090
α2 globulin 1.62 ± 0.51 5.05 (1.84-13.8) 0.00164
Constant −8.48 ± 1.75
In the stepwise multiple regression analysis, 3.2-10.5% α2 globulin, 66–288 U/l LDH, radical nephrectomy and complete resection of thrombus without metastasis
in surgical category, <8.3-cm tumor size, and non-venous wall-invasive thrombus in RV/IVC wall invasion are coded as 1.
Similarly, 10.6-22.3% α2 globulin, 289–1740 U/l LDH, radical nephrectomy and complete resection of thrombus with metastases that has undergone a
cytoreductive surgery in surgical category, 8.5-27.0-cm tumor size, and venous wall-invasive thrombus in RV/IVC wall invasion are coded as 2.
Radical nephrectomy and complete resection of thrombus with unresected metastases, radical nephrectomy and incomplete resection of thrombus regardless of
metastatic status, and abandoned operation in surgical category are coded as 3, 4, and 5, respectively.
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http://www.biomedcentral.com/1471-2407/13/447of predictors of OS were performed using the restricted
follow-up data until 1, 2, and 3 years after intervention
against RCC. Overall, fewer global factors were predictive
of OS regardless of the follow-up duration, and most
independent predictive factors may have changed with
follow-up duration. Significant independent predictive
factors for a short (within 1 year) and short-to-intermedi-
ate (within 1 or 2 years) follow-up period were tumor size
and RV/IVC wall invasion, respectively. The surgical
category was very strongly correlated with OS in restricted
data on follow-up duration within 1, 2, or 3 years. More
aggressive tumor removal for origin including venous
thrombus might affect survivals. In general, a study inves-
tigating the impact of surgery may not include patients
with metastatic cases in the cohort. In the present study, a
univariate analysis revealed that 5-year all-cause of death
in patents with distant metastases was significant higher
(68.6%) than that in those without distant metastases
(48.7%). However, about a half of patients without distant
metastases at the diagnosis was dead mainly due to
progressing distant metastases after any intervention.
It may means that some patients with venous thrombus
may have had invisible distant metastases before surgery.
It is also hypothesized that some patients actually did nothave any distant metastases at the diagnosis, but unstable
tumor cell extending to venous system might disseminate
during surgical intervention or residual tumor cells in the
venous wall or perirenal fat following surgery might be an
origin of progressing distant metastases during long-term
follow-up. Therefore, we did not exclude patients with
visible distant metastases in the present study. Then, a
multivariate Cox proportional hazards model showed that
presence or absence of visible distant metastases at the
diagnosis was not an independent prognostic factor to
predict OS in patients with renal cell carcinoma extending
into venous system. The level of tumor thrombus setting
the cut-line between patients with a thrombus that ex-
tended within the RV and those with a thrombus that
extended into the IVC was included in the multivariate
logistic regression analyses, but it was not an independent
predictive factor for OS using any restricted follow-up
duration.
For postoperative follow-up at an outpatient clinic, it
would be useful to investigate changes in predictive
factors with elapsed time after intervention. In the
present study, multivariate Cox proportional hazards
models were used to investigate predictors of OS not only
using the full-range follow-up data of all participants, but
(A)
(B)
Figure 2 Overall survivals. (A) stratified by surgical categories (surgical category 1; radical nephrectomy and complete resection of thrombus
without any metastases, surgical category 2 + 3; radical nephrectomy and complete resection of thrombus regardless of cytoreductive surgery at
metastatic regions, surgical category 4 + 5; radical nephrectomy and incomplete resection of thrombus regardless of metastatic status or
abandoned operation), (B) stratified by the status of renal vein (RV) or inferior vena cava (IVC) wall invasion.
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http://www.biomedcentral.com/1471-2407/13/447also those of survivors at 1, 2, and 3 years of follow-up.
RV/IVC wall invasion was significantly related to OS in
full-range follow-up data and in survivors at 2 and 3 yearsof follow-up. The surgical category was significantly re-
lated to OS using unrestricted datasets. Investigation of
survivors at 1, 2, and 3 years of follow-up showed that
Hirono et al. BMC Cancer 2013, 13:447 Page 13 of 14
http://www.biomedcentral.com/1471-2407/13/447many independent predictive factors were not universal
at any follow-up period and changed accordingly. For
example, IAP was very strongly related to OS in survivors
at 1 year of follow-up, but not predictive in limited survi-
vors at 2 and 3 years of follow-up.
According to the Union for International Cancer Control
(UICC) TNM classification published in 2002, RCC with a
tumor thrombus was classified as T3b or T3c regardless of
the presence or absence of perirenal fat invasion or adrenal
direct invasion. Recently, some investigators demonstrated
the independent and positive impact of adrenal, perirenal
fat, or renal sinus invasion on survival [23-28]. In the
present series, only 157 (53.8% of all participants) patients
had data on the status of renal capsular invasion. Although
the present study could not demonstrate independent sig-
nificance of the presence of renal capsular invasion on OS,
the significance of local invasion on survival in RCC
extending into venous systems cannot be concluded.
A wide-range registration period during 30 years may
be a flaw of the present study because diagnostic quality
of CT scan especially in 8 patients diagnosed in 1980’s
could not be enough. Those 8 patients diagnosed in 1980’s
were followed until between 1994 and 2003 (during
145 months in median). Therefore, recurrence after
intervention could be checked using more reliable CT
imaging with time. Among 8 patients, 7 were diagnosed
after 1987 and the oldest patient was diagnosed in 1980.
The oldest case was dead due to progressing distant
metastases, but was alive until the end of 2003. Therefore,
we did not exclude those important patients diagnosed in
1980’s and followed for a long-term from the present
study. The present retrospective multi institutional study
included some flaws in the quality of database. There were
some missing data on pretreatment clinical factors and
pathological findings. However, there were only 6 factors
(e.g.; ESR, α2 globulin, Ca, IAP, N category in TNM classi-
fication and capsular status) that included 30% or more
unknown data in each among 22 pretreatment, treatment
and pathological factors using Kaplan-Meier analysis
on overall survival (shown in Table 4). Lacking restricted
follow-up strategy could be a flaw of the present retrospect-
ive study. If a surrogate endpoint such as progression-free
survival was set as a primary endpoint, likelihood of mis-
classification of the event would not be ignored. However,
overall survival was set as a primary endpoint in the
present study. Therefore, likelihood of misclassification of
the event may not affect the conclusions and could not be
a serious flaw in the present study.
In the present series, all follow-up data were retrospect-
ively registered in the era before introduction of molecular-
targeted therapy in Japan. It is necessary to investigate
the usefulness of neoadjuvant, adjuvant, or salvage mo-
lecular targeted therapy in a nationwide or international
prospective study. Furthermore, the present finding onthe importance of RV/IVC invasion certainly raises
important questions on the need of IVC excision in patients
with tumor thrombus invading to venous wall and for
imaging techniques to be improved so that IVC invasion
can be identified pre-operatively. The predictive impact
of modern imaging technique such as multi-slice CT and
3-tesla magnetic resonance imaging (MRI) on likelihood
of venous wall invasion and prognostic impact of follow-
ing IVC excision should be also prospectively investigated
in the future.
Conclusions
In patients diagnosed with an advanced stage of RCC
with a tumor thrombus, many important independent
predictive factors were identified in each subgroup analysis
in terms of restricted follow-up duration and yearly-based
survivors. However, the most universal factors affecting
improvement of both in short-term and long-term sur-
vivals in RCC with venous thrombus could be feasible
aggressive cytoreductive operation and absence of venous
wall invasion even in a case of metastatic disease. It
may mean that the best available cytoreductive operation
following more reliable preoperative imaging for predicting
venous wall invasion status would improve OS for patients
with advanced RCC extending into venous systems.
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